Targets › ADRA2B
39 programs from 38 companies in 141 trials: 51 Phase 4, 42 Phase 2, 25 Phase 3, 23 Phase 1; Psychiatry, Other, Ophthalmology; next expected readout Nov 2026.
Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that activate G(i/o) protein pathway, thereby promoting adenylyl cyclase inhibition, ERK1/2 stimulation, and voltage-gated calcium channels suppression. Control a variety of physiological processes, such as regulation of blood pressure, lipolysis and insulin release. (UniProt, P18089)
Open in Phaseline: the race on ADRA2B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pharmazz | Centhaquine (LYFAQUIN™) α2B-adrenergic receptor agonist (venous) and α2A-adrenergic receptor agonist (arterial); e | ADRA2B, ADRA2A | Phase 4 | Hypovolemic Shock | Nov 2026 |
| University of Pennsylvania | 2-[18F]-FA Voltage-gated calcium channel modulator | CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STN | Phase 4 | Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis … | Nov 2026 |
| Cooper Norcross Health | Clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 4 | Neonatal Abstinence Syndrome | Dec 2026 |
| Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, | Brimonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 4 | Glaucoma | Dec 2026 |
| Sunnybrook Health Sciences Centre | Dexmedetomidine Hydrochloride Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 4 | Delirium | Dec 2026 |
| John O'Toole | Clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 4 | Lumbar Spinal Stenosis | Feb 2027 |
| Peking University First Hospital | Intranasal dexmedetomidine-esketamine Combination of alpha-2 adrenergic agonist and NMDA receptor antagonist | ADRA2A, NMDAR, ADRA2B, ADRA2C, GRIN1 | Phase 4 | Adenotonsillectomy; General Anesthesia | Feb 2027 |
| Region Skane | Clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 4 | Osteo Arthritis of the Knee | Mar 2027 |
| University of Sao Paulo General Hospital | clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 4 | Cocaine Use Disorder | Jul 2027 |
| University Hospital Dubrava | clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 4 | Inguinal Hernia | Sep 2027 |
| Damanhour Teaching Hospital | Dexmedetomidine Hydrochloride Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 4 | Analgesia | Dec 2027 |
| Columbia University | Clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 4 | Cesarean Delivery | May 2028 |
| Children's Hospital Medical Center, Cincinnati | Guanfacine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 4 | Attention-Deficit/Hyperactivity Disorder (ADHD) | Feb 2030 |
| Prairie Eye Center | Simbrinza Alpha-2 adrenergic receptor agonist and carbonic anhydrase inhibitor | ADRA2A, ADRA2B | Phase 4 | Open Angle Glaucoma | – |
| Alcon Research | Apraclonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 3 | Ocular Hyperemia | Jan 2027 |
| Wake Forest University Health Sciences | Clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 3 | PTSD | Mar 2027 |
| Stanford University | Tizanidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 3 | Chronic Pain | Jan 2028 |
| Acer Therapeutics | Celiprolol (ACER-002) Beta-2 adrenergic receptor partial agonist; Adrenergic receptor alpha-2 antagonist; Beta-1 adrenergic receptor antagonist | ADRB2, ADRA2A, ADRA2C, ADRA2B, ADRB1 | Phase 3 | Vascular Ehlers-Danlos Syndrome | Mar 2029 |
| University of Maryland, Baltimore | Lofexidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Opioid Withdrawal | Nov 2026 |
| Washington State University | Mirtazapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist | HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2B | Phase 2 | Stimulant Use Disorder | Dec 2026 |
| University of Trieste | mirtazapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist | HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2B | Phase 2 | RETT Syndrome With Proven MECP2 Mutation | Dec 2026 |
| Teikoku Pharma USA | Dexmedetomidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Agitation | May 2027 |
| M.D. Anderson Cancer Center | Mirtazapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist | HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2B | Phase 2 | Advanced Cancer | Dec 2027 |
| Copenhagen University Hospital, Rigshospitalet | Clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Emergence Delirium | Jan 2028 |
| Hartford Hospital | Tizanidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Post Operative | Jul 2028 |
| Stanford University | Guanfacine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Depression | Oct 2028 |
| Indiana University | Guanfacine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Alcohol Use Disorder | Aug 2029 |
| University of California, Irvine | Mirtazapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist | HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2B | Phase 2 | Glioma of Brain | Dec 2030 |
| Universidade Federal do Rio de Janeiro | Clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Hernia, Umbilical | – |
| Guangzhou Novaken Pharm | Dexmedetomidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Preoperative Sedation; Emergence Delirium; Laceration of Skin; Vaginal Delivery … | – |
| Yale University | Guanfacine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Alcohol Use | – |
| Orygen | Guanfacine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Cannabis Use Disorder | – |
| BioCorRx Pharmaceuticals Inc | Lofexidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Opioid Withdrawal (Disorder) | – |
| Tarian Pharma | TAR-0520 Gel Brimonidine tartrate - selective alpha-2 adrenergic receptor agonist | ADRA2A, ADRA2B, ADRA2C | Phase 2 | EGFR Inhibitor-associated Rash | – |
| BioXcel Therapeutics | Dexmedetomidine (BXCL501) Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 1 | Schizophrenia | Jul 2027 |
| University of Kansas Medical Center | Clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 1 | Blood Pressure | Aug 2027 |
| Satish R. Raj | Clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 1 | Tachycardia | Dec 2029 |
| Research Institute of Ophthalmology, Egypt | Dexmedetomidine Hydrochloride Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 1 | Patients Undergoing External Dacrocystorhinostomy Operations | – |
| Rutgers, The State University of New Jersey | Guanfacine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 1 | Mindfulness | – |
Delirium (4) Emergence Delirium (3) Breast Cancer (3) Anesthesia (3) Alcohol Use Disorder (3) Laceration of Skin (2) Postoperative Pain (2) General Anesthesia (2) Cesarean Delivery (2) Insomnia (2) Agitation (2) Mental Disorder (2)
small molecule (35), protein or peptide (2), mixed (1)
Stanford University (2) University of Kansas Medical Center (1) Guangzhou Novaken Pharm (1) Copenhagen University Hospital, Rigshospitalet (1) Universidade Federal do Rio de Janeiro (1) Wake Forest University Health Sciences (1) M.D. Anderson Cancer Center (1) Indiana University (1) Research Institute of Ophthalmology, Egypt (1) University of Maryland, Baltimore (1) Pharmazz (1) University Hospital Dubrava (1) Rutgers, The State University of New Jersey (1) BioXcel Therapeutics (1) Washington State University (1) Teikoku Pharma USA (1) Sunnybrook Health Sciences Centre (1) Hartford Hospital (1) University of California, Irvine (1) Tarian Pharma (1)
ADRA2A (39) ADRA2C (37) HTR2A (5) HTR2C (5) CHRNA4 (1) OPRK1 (1) OPRD1 (1) OPRM1 (1) UL51 (1) Ion channels (1) CACNB4 (1) CACNB2 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.